China’s biotech industry sees global expansion as unstoppable, despite US pressure

Chinese biotech firms are continuing their global expansion, a trend described as "irreversible" by industry insiders. This expansion is proceeding despite US investment restrictions and national security measures designed to impede their progress. According to Zhang Jun of Citic Securities, the US has implemented regulatory and non-tariff barriers for Chinese companies entering the American market. However, Chinese biotech companies are increasingly commercializing their products internationally, particularly in Europe. In European markets, governments are reportedly more open to Chinese innovative drugs and medical devices due to their cost-performance advantages, especially amid tight fiscal conditions.